IJIbo Janssens

Ibo Janssens

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ibo Janssens has a total of 28 co-authors. Here are the top co-authors by number of shared publications:

  • Nathalie Cools

    Laboratory of Experimental Hematology, Vaccine & Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp, 2610 Antwerp, Belgium

    4 shared publications
  • Inez Wens

    Laboratory of Experimental Hematology Vaccine and Infections Disease Institute (VAXINFECTIO) Faculty of Medicine and Health Sciences University of Antwerp Antwerp Belgium

    2 shared publications
  • Jasper Van Den Bos

    Laboratory of Experimental Haematology, Vaccine and Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences University of Antwerp Antwerp Belgium

    2 shared publications
  • Judith Derdelinckx

    Laboratory of Experimental Hematology, Vaccine and Infectious Disease Institute (VaxInfectio), Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium; Division of Neurology, Antwerp University Hospital, Edegem, Belgium

    2 shared publications
  • Nathalie Cools

    Laboratory of Experimental Hematology Vaccine and Infections Disease Institute (VAXINFECTIO) Faculty of Medicine and Health Sciences University of Antwerp Antwerp Belgium

    2 shared publications
  • Amber Dams

    Laboratory of Experimental Hematology Vaccine and Infections Disease Institute (VAXINFECTIO) Faculty of Medicine and Health Sciences University of Antwerp Antwerp Belgium

    1 shared publication

Latest Publications

  • Open Access

    The Efficiency of Brain‐Derived Neurotrophic Factor Secretion by mRNA‐Electroporated Regulatory T Cells Is Highly Impacted by Their Activation Status

    by Jasper Van Den Bos, Ibo Janssens, Morgane Vermeulen, Amber Dams, Hans De Reu, Stefanie Peeters, Carole Faghel, Yousra El Ouaamari, Inez Wens, Nathalie Cools

    Genetic engineering of regulatory T cells (Tregs) presents a promising avenue for advancing immunotherapeutic strategies, particularly in autoimmune diseases and transplantation. This study explores the modification of Tregs via mRNA electroporation, investigating the influence of T‐cell activation status on transfection efficiency, phenotype, and functionality. For this CD45RA+ Tregs were isolated, expanded, and modified to overexpress brain‐derived neurotrophic factor (BDNF). Kinetics of BDNF expression and secretion were explored. Treg activation state was assessed by checking the expression of activation markers CD69, CD71, and CD137. Our findings show that only activated Tregs secrete BDNF post‐genetic engineering, even though both activated and resting Tregs express BDNF intracellularly. Notably, the mTOR pathway and CD137 are implicated in the regulation of protein secretion in activated Tregs, indicating a complex interplay of signalling pathways. This study contributes to understanding the mechanisms governing protein expression and secretion in engineered Tregs, offering insights for optimizing cell‐based therapies and advancing immune regulation strategies.


  • Open Access

    Tolerogenic Dendritic Cells Induce Apoptosis-Independent T Cell Hyporesponsiveness of SARS-CoV-2-Specific T Cells in an Antigen-Specific Manner

    by Mats Van Delen, Ibo Janssens, Amber Dams, Laurence Roosens, Benson Ogunjimi, Zwi N. Berneman, Judith Derdelinckx, Nathalie Cools

    Although the global pandemic caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is still ongoing, there are currently no specific and highly efficient drugs for COVID-19 available, particularly in severe cases. Recent findings demonstrate that severe COVID-19 disease that requires hospitalization is associated with the hyperactivation of CD4+ and CD8+ T cell subsets. In this study, we aimed to counteract this high inflammatory state by inducing T-cell hyporesponsiveness in a SARS-CoV-2-specific manner using tolerogenic dendritic cells (tolDC). In vitro-activated SARS-CoV-2-specific T cells were isolated and stimulated with SARS-CoV-2 peptide-loaded monocyte-derived tolDC or with SARS-CoV-2 peptide-loaded conventional (conv) DC. We demonstrate a significant decrease in the number of interferon (IFN)-γ spot-forming cells when SARS-CoV-2-specific T cells were stimulated with tolDC as compared to stimulation with convDC. Importantly, this IFN-γ downmodulation in SARS-CoV-2-specific T cells was antigen-specific, since T cells retain their capacity to respond to an unrelated antigen and are not mediated by T cell deletion. Altogether, we have demonstrated that SARS-CoV-2 peptide-pulsed tolDC induces SARS-CoV-2-specific T cell hyporesponsiveness in an antigen-specific manner as compared to stimulation with SARS-CoV-2-specific convDC. These observations underline the clinical potential of tolDC to correct the immunological imbalance in the critically ill.


  • Treatment of in vitro generated Langerhans cells with JAK-STAT inhibitor reduces their inflammatory potential

    by Sterkens Ann, Janssens Ibo, Meena Megha, De Reu Hans, Van Bruggen Laura, Lambert Julien, Bervoets An, Cools Nathalie

    Alopecia areata (AA) is a condition in which hair is lost in small regions or over the entire body. It has a prevalence of 1 in 1000 and has a great impact on psychological wellbeing. AA is generally considered an autoimmune disease in which a collapse of the immune privilege system of the hair follicle has shown to play an important role, potentially driven by interferon gamma (IFN-γ). The most prominent cells located in or around the hair follicle in AA are Langerhans cells, CD4+ or CD8+ T cells, macrophages and mast cells. Langerhans cells, specialized dendritic cells, are resident in the epidermis and are known to associate with hair follicles. Therefore, we aimed to develop in vitro generated Langerhans cells contributing as an in vitro model of disease. In vitro models provide insight into the behaviour of cells and are a valuable tool before being in need of an animal model or patient samples. For this, Langerhans-like cells were generated from CD14+ monocytes in the presence of GM-CSF and TGF-β. After 10 days of cell culture, Langerhans-like cells express CD207 and CD1a but lack CD209 expression as well as Birbeck granules. Next, Langerhans-like cells were exposed to inflammatory conditions and the effect of different AA treatments was investigated. All treatments—diphencyprone contact immunotherapy, UV-B light therapy and JAK-STAT inhibition—affect the expression of costimulatory and skin-homing markers on Langerhans-like cells. Importantly, also the T cell stimulatory capacity of Langerhans-like cells was significantly reduced following treatment under inflammatory conditions. Noteworthy, JAK-STAT inhibition outperformed conventional AA treatments. In conclusion, our findings demonstrate that in vitro generated Langerhans-like cells can be used as a model of disease. Moreover, JAK-STAT inhibition may become a valuable new approach for the treatment of AA.


  • Open Access

    Engineering of regulatory T cells by means of mRNA electroporation in a GMP-compliant manner

    by Ibo Janssens, Diana Campillo Davó, Jasper Van Den Bos, Hans De Reu, Zwi N. Berneman, Inez Wens, Nathalie Cools


  • Open Access

    Made to Measure: Patient-Tailored Treatment of Multiple Sclerosis Using Cell-Based Therapies

    by Inez Wens, Ibo Janssens, Judith Derdelinckx, Megha Meena, Barbara Willekens, Nathalie Cools

    Currently, there is still no cure for multiple sclerosis (MS), which is an autoimmune and neurodegenerative disease of the central nervous system. Treatment options predominantly consist of drugs that affect adaptive immunity and lead to a reduction of the inflammatory disease activity. A broad range of possible cell-based therapeutic options are being explored in the treatment of autoimmune diseases, including MS. This review aims to provide an overview of recent and future advances in the development of cell-based treatment options for the induction of tolerance in MS. Here, we will focus on haematopoietic stem cells, mesenchymal stromal cells, regulatory T cells and dendritic cells. We will also focus on less familiar cell types that are used in cell therapy, including B cells, natural killer cells and peripheral blood mononuclear cells. We will address key issues regarding the depicted therapies and highlight the major challenges that lie ahead to successfully reverse autoimmune diseases, such as MS, while minimising the side effects. Although cell-based therapies are well known and used in the treatment of several cancers, cell-based treatment options hold promise for the future treatment of autoimmune diseases in general, and MS in particular.